tetano
Editor, Senior Moderator
J Geriatr Oncol
. 2021 Jun 11;S1879-4068(21)00136-3.
doi: 10.1016/j.jgo.2021.06.002. Online ahead of print.
Serological response to COVID-19 vaccination in patients with cancer older than 80 years
Daniela Iacono[SUP] 1 [/SUP], Linda Cerbone[SUP] 1 [/SUP], Lucia Palombi[SUP] 2 [/SUP], Elena Cavalieri[SUP] 3 [/SUP], Isabella Sperduti[SUP] 4 [/SUP], Rosario Andrea Cocchiara[SUP] 5 [/SUP], Bruno Mariani[SUP] 6 [/SUP], Gabriella Parisi[SUP] 6 [/SUP], Carlo Garufi[SUP] 7 [/SUP]
Affiliations
Abstract
Central studies carried out on vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-COV2) excluded patients receiving immunosuppressive therapy and those diagnosed with an immunosuppressive condition. Moreover, there are no data on vaccine efficacy regarding older patients with cancer.
Objectives: The primary objective was to evaluate the seroprevalence of the SARS-CoV2 IgG in older patients (aged ≥80 years) diagnosed with solid or hematological malignancies, one month after administering the second dose of the BNT162b2 vaccine.
Materials and methods: We screened 74 older patients with cancer, 45 of them accepted to receive the vaccination and collected serum samples from 36 patients; a group of medical doctors and nurses from our hospital was used as a control in a 1:2 ratio.
Results: The median age was 82 years (range 80-89). Median serum IgG were 2396,10 AU/ml (range 0-32,763,00) in patients with cancer and 8737,49 AU/ml (398.90-976,280,00) in the control group, p < 0.0001. Additional subgroup analyses were performed comparing males and females, patients treated with chemotherapy versus other therapies (immunotherapy, targeted therapy), solid tumors versus hematological malignancies, early (I-II) versus advanced (III-IV) stage of disease, continuative corticosteroid use or not. None of them reached statistical significance.
Conclusion: Our study shows for the first time that patients with cancer aged ≥80 years can have a serological response to the BNT162b2 COVID-19 vaccine one month after vaccination and consequently support the vaccination campaign currently underway in this frail population.
. 2021 Jun 11;S1879-4068(21)00136-3.
doi: 10.1016/j.jgo.2021.06.002. Online ahead of print.
Serological response to COVID-19 vaccination in patients with cancer older than 80 years
Daniela Iacono[SUP] 1 [/SUP], Linda Cerbone[SUP] 1 [/SUP], Lucia Palombi[SUP] 2 [/SUP], Elena Cavalieri[SUP] 3 [/SUP], Isabella Sperduti[SUP] 4 [/SUP], Rosario Andrea Cocchiara[SUP] 5 [/SUP], Bruno Mariani[SUP] 6 [/SUP], Gabriella Parisi[SUP] 6 [/SUP], Carlo Garufi[SUP] 7 [/SUP]
Affiliations
- PMID: 34175246
- DOI: 10.1016/j.jgo.2021.06.002
Abstract
Central studies carried out on vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-COV2) excluded patients receiving immunosuppressive therapy and those diagnosed with an immunosuppressive condition. Moreover, there are no data on vaccine efficacy regarding older patients with cancer.
Objectives: The primary objective was to evaluate the seroprevalence of the SARS-CoV2 IgG in older patients (aged ≥80 years) diagnosed with solid or hematological malignancies, one month after administering the second dose of the BNT162b2 vaccine.
Materials and methods: We screened 74 older patients with cancer, 45 of them accepted to receive the vaccination and collected serum samples from 36 patients; a group of medical doctors and nurses from our hospital was used as a control in a 1:2 ratio.
Results: The median age was 82 years (range 80-89). Median serum IgG were 2396,10 AU/ml (range 0-32,763,00) in patients with cancer and 8737,49 AU/ml (398.90-976,280,00) in the control group, p < 0.0001. Additional subgroup analyses were performed comparing males and females, patients treated with chemotherapy versus other therapies (immunotherapy, targeted therapy), solid tumors versus hematological malignancies, early (I-II) versus advanced (III-IV) stage of disease, continuative corticosteroid use or not. None of them reached statistical significance.
Conclusion: Our study shows for the first time that patients with cancer aged ≥80 years can have a serological response to the BNT162b2 COVID-19 vaccine one month after vaccination and consequently support the vaccination campaign currently underway in this frail population.